Carlo Genova· @CarloGenova5 · X·· 15 hours agoScore70
Body · original
Standing ovation at #ESMO2026 for DELLPHI-305. It is heart-warming to see a meaningful survival advantage in ED-SCLC.
105 views · 1 like · 1 repost · 0 replies
Conference abstracts
LBA3matched by Presidential Symposium I
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: Carlo Genova · x.com